Goldman Sachs raised the firm’s price target on Immunovant (IMVT) to $32 from $29 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
- Strengthening the Buy Case for IMVT-1402: Targeted Phase 3 Graves’ Disease Strategy and Reproducible Efficacy Support Commercial Potential
- Midday Fly By: Amazon said to eye Globalstar, Tesla deliveries miss consensus
- Buy Rating Maintained on Immunovant as IMVT-1402 Pipeline Overshadows Batoclimab Setback
- Immunovant price target lowered to $50 from $52 at Leerink